Inborn errors of metabolism:

Indications for: DOJOLVI

As a source of calories and fatty acids for the treatment of patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Adults and Children:

See full labeling. Discontinue other MCT products prior to initiation. Determine daily caloric intake (DCI) prior to calculating dose. Total daily dose (mL) = Patients DCI (kcal) x Target % doses of DCI/8.3 (kcal/mL) of Dojolvi. Give at mealtimes or with snacks. Administer dose mixed with semi-solid food or liquids (eg, yogurt, milk, formula, cottage cheese, hot cereal, applesauce, baby food, others) orally or enterally via feeding tube. Target daily dose: up to 35% of total prescribed DCI in at least 4 divided doses. Not currently taking medium-chain triglyceride (MCT) product: initiate at total daily dose of ~10% DCI in at least 4 divided doses, then increase up to 35% DCI over 2–3 weeks. Switching from another MCT product: initiate at last tolerated MCT daily dose in at least 4 divided doses, then increase by ~5% DCI every 2–3 days until up to 35% DCI is achieved.

DOJOLVI Warnings/Precautions:

Incompatible with certain plastics. Do not use polystyrene or polyvinyl chloride (PVC) plastics for preparation or administration. Monitor containers, dosing components/utensils, or feeding tubes regularly to ensure proper functioning and integrity. Monitor total caloric intake during dose titration (esp. in those with GI adverse reactions) and adjust as needed. If GI reactions occur, consider dose reduction until symptoms resolved. Avoid in pancreatic insufficiency. Neonates: may require higher fat intake. Pregnancy. Nursing mothers.

DOJOLVI Classification:

Medium-chain triglyceride.

DOJOLVI Interactions:

Avoid use with pancreatic lipase inhibitors (eg, orlistat).

Adverse Reactions:

Abdominal pain, diarrhea, vomiting, nausea.

Generic Drug Availability:


How Supplied: